Bayer Temporarily Suspends Global Trasylol® Marketing
- Details
- Category: Bayer
Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol® (aprotinin injection) until final results from the Canadian BART trial can be compiled, received and evaluated.
Novo Nordisk celebrates 75-year commitment to diabetes research
- Details
- Category: Novo Nordisk
Novo Nordisk celebrates two milestone anniversaries, which demonstrates the company's long-term commitment to diabetes care and research. The day marks the 75-year anniversary of the Steno Diabetes Center and the 50-year anniversary of the Hagedorn Research Institute.
Taisho and Pfizer Sign a Letter of Intent for Taishoâs Schizophrenia Drug Candidate
- Details
- Category: Pfizer
Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) and Pfizer Inc. [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage. The letter of intent relates to a proposed license agreement regarding rights for development and commercialization of the substance outside Japan.
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
- Details
- Category: Novartis
Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec® (imatinib)*, an established treatment standard and a leading Novartis medicine.
Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension
- Details
- Category: Product
Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol significantly reduced sitting diastolic and systolic blood pressure used as monotherapy among African-American patients with stage I-II hypertension.
Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer. Nexavar, an oral anti-cancer drug, is the first and only approved systemic drug therapy for liver cancer and the only drug therapy shown to significantly improve overall survival in patients with the disease.
Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc.
- Details
- Category: Nycomed
Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc., a company focused on niche therapeutic markets in the USA. The acquisition will add further branded dermatologics to the PharmaDerm division of Nycomed US and will provide an enhanced platform for in-licensing and co-promotion of dermatology products. The transaction is subject to the receipt of Bradley shareholder approval and approval by competition authorities. It is expected to close in the first quarter of 2008.
More Pharma News ...
- Pfizer to Appeal German Court Decision in Lipitor Patent Case
- GSK reports third quarter EPS of 23.7p
- Bristol-Myers Squibb Company Reports Financial Results
- Bayer Issues Additional Guidance to Physicians on Trasylol®
- One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Named to Science Magazine's List of Top Employers
- Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent